Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Authors
Keywords
Crohn's Disease, Ulcerative colitis, Thiopurines, Calcineurin inhibitors, Biologics, Combination therapy
Journal
AUTOIMMUNITY REVIEWS
Volume 20, Issue 6, Pages 102832
Publisher
Elsevier BV
Online
2021-04-16
DOI
10.1016/j.autrev.2021.102832
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
- (2020) Qi Zhao BIODRUGS
- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
- (2020) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial
- (2020) Xavier Roblin et al. GUT
- Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease
- (2020) Edward Yang et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab
- (2020) Ahmed Elmoursi et al. INFLAMMATORY BOWEL DISEASES
- The Use of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
- (2020) Kerri Glassner et al. Journal of Digestive Diseases
- Management of IBD during the COVID-19 outbreak: resetting clinical priorities
- (2020) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
- (2020) Christine Olbjørn et al. PEDIATRIC DRUGS
- Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
- (2020) Franco Scaldaferri et al. United European Gastroenterology Journal
- Letter: combination of biologics in inflammatory bowel diseases
- (2020) Mathurin Fumery et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis
- (2020) Tamás Resál et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications
- (2020) Franco Scaldaferri et al. INFLAMMATORY BOWEL DISEASES
- Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab
- (2020) Giuseppe Biscaglia et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn’s Disease
- (2020) Christina Dimopoulos et al. INFLAMMATORY BOWEL DISEASES
- Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
- (2019) Chao Chen et al. INFLAMMATORY BOWEL DISEASES
- Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review
- (2019) Dong Yeon Jeong et al. AUTOIMMUNITY REVIEWS
- Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent
- (2019) Veronika Polakovicova et al. DIGESTIVE AND LIVER DISEASE
- The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
- (2019) Alvilde Maria Ossum et al. INFLAMMATORY BOWEL DISEASES
- Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
- (2019) Davide Giuseppe Ribaldone et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Ulcerative Colitis and Crohn’s Disease Have the Same Burden and Goals for Treatment
- (2019) Catherine Le Berre et al. Clinical Gastroenterology and Hepatology
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors
- (2019) Daniela Pugliese et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2019) Michael M. Ward et al. ARTHRITIS CARE & RESEARCH
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
- (2019) Joana Torres et al. Journal of Crohns & Colitis
- Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis
- (2019) Jacob E. Ollech et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab
- (2018) F. S. Macaluso et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
- (2018) S. Singh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry
- (2018) Geert D’Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
- (2018) Britt Christensen et al. Clinical Gastroenterology and Hepatology
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
- (2018) Robert P. Hirten et al. Clinical Gastroenterology and Hepatology
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
- (2018) Julien Kirchgesner et al. GASTROENTEROLOGY
- The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study
- (2018) Fabio Salvatore Macaluso et al. INFLAMMATORY BOWEL DISEASES
- Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
- (2018) Lydia C T Buer et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
- (2018) Lian Cui et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis
- (2018) Jingjing Lv et al. Molecular Pain
- Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy
- (2018) Catherine Le Berre et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis
- (2018) Gauthier Pellet et al. Clinical Gastroenterology and Hepatology
- Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy—a Post-hoc analysis
- (2018) Jean Frederic Colombel et al. Clinical Gastroenterology and Hepatology
- Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies
- (2018) Laurent Peyrin-Biroulet et al. AUTOIMMUNITY REVIEWS
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis
- (2018) Katherine M. Stiff et al. Expert Review of Clinical Pharmacology
- Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohnʼs Disease
- (2017) Viraj C. Kariyawasam et al. INFLAMMATORY BOWEL DISEASES
- Systematic Review and Meta-analysis
- (2017) Jean M. Chalhoub et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohnʼs Disease
- (2017) Kayci Huff-Hardy et al. INFLAMMATORY BOWEL DISEASES
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents: Cyclosporine Plus Vedolizumab
- (2017) Kata Szántó et al. Journal of Crohns & Colitis
- Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy
- (2017) Xavier Roblin et al. Journal of Crohns & Colitis
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
- (2017) Tal Engel et al. Journal of Crohns & Colitis
- Safety of biologics in psoriasis
- (2017) Masahiro Kamata et al. JOURNAL OF DERMATOLOGY
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
- (2017) Carl Eriksson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
- (2017) Lieke M Spekhorst et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
- (2016) J. Cosnes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
- (2016) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids
- (2016) Neeraj Narula et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
- (2016) G. R. Gunn et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
- (2016) Edward Shelton et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience
- (2016) Laurent Peyrin-Biroulet et al. Journal of Crohns & Colitis
- The ATG16L1 risk allele associated with Crohn’s disease results in a Rac1-dependent defect in dendritic cell migration that is corrected by thiopurines
- (2016) M E Wildenberg et al. Mucosal Immunology
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
- (2015) M. Rosario et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis
- (2015) D. Christophorou et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
- (2015) D. Pugliese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease
- (2015) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
- (2015) Jennifer L. Jones et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
- (2015) David Drobne et al. Clinical Gastroenterology and Hepatology
- The safety of calcineurin inhibitors for kidney-transplant patients
- (2015) Paolo Malvezzi et al. Expert Opinion On Drug Safety
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
- (2015) Marcus Harbord et al. Journal of Crohns & Colitis
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- (2015) Reena Khanna et al. LANCET
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
- (2014) Parambir S Dulai et al. GUT
- Influence of Combination Therapy with Immune Modulators on Anti-TNF Trough Levels and Antibodies in Patients with IBD
- (2014) Tamara van Schaik et al. INFLAMMATORY BOWEL DISEASES
- Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis
- (2014) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- (2014) Uri Kopylov et al. Journal of Crohns & Colitis
- Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis
- (2014) Michael J Hayes et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Infliximab in Steroid-dependent Ulcerative Colitis
- (2013) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- Addition of Thiopurines Can Recapture Response in Patients with Crohn's Disease who Have Lost Response to Anti-Tnf Monotherapy
- (2013) David EH Ong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
- (2012) C. Reenaers et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study
- (2012) Gilaad G Kaplan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
- (2012) Ingrid Ordás et al. Clinical Gastroenterology and Hepatology
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
- (2011) Laurent Peyrin–Biroulet et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro
- (2011) Anne Christine W. Vos et al. INFLAMMATORY BOWEL DISEASES
- Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
- (2010) Anne Christine W. Vos et al. GASTROENTEROLOGY
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2009) J.F. Rahier et al. Journal of Crohns & Colitis
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
- (2009) Laurent Beaugerie et al. LANCET
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now